NOTE: Please save this file locally before filling in the table, DO NOT work on the file within your internet browser as changes will not be saved. Adobe Acrobat Reader (available free here) is recommended for completion.

ARRIVE The ARRIVE guidelines 2.0: author checklist

The ARRIVE Essential 10

These items are the basic minimum to include in a manuscript. Without this information, readers and reviewers cannot assess the reliability of the findings.

ltem		Recommendation	Section/line number, or reason for not reporting
Study design	1	For each experiment, provide brief details of study design including:	Methods/line
		a. The groups being compared, including control groups. If no control group has been used, the rationale should be stated.	109-120
		b. The experimental unit (e.g. a single animal, litter, or cage of animals).	Methods/line 109-120
Sample size	2	a. Specify the exact number of experimental units allocated to each group, and the total number in each experiment. Also indicate the total number of animals used.	Methods/line 109-120
		b. Explain how the sample size was decided. Provide details of any <i>a priori</i> sample size calculation, if done.	Methods/line 109-120
Inclusion and exclusion criteria	3	a. Describe any criteria used for including and excluding animals (or experimental units) during the experiment, and data points during the analysis. Specify if these	Methods/line 94-102
		criteria were established <i>a priori</i>. If no criteria were set, state this explicitly.b. For each experimental group, report any animals, experimental units or data points	Methods/line 109-120
		not included in the analysis and explain why. If there were no exclusions, state so. c. For each analysis, report the exact value of <i>n</i> in each experimental group.	Methods/line 109-120
Randomisation	4	 State whether randomisation was used to allocate experimental units to control and treatment groups. If done, provide the method used to generate the randomisation sequence. 	Methods/line 109-120
		b. Describe the strategy used to minimise potential confounders such as the order of treatments and measurements, or animal/cage location. If confounders were not controlled, state this explicitly.	Methods/line 109-120
Blinding	5	Describe who was aware of the group allocation at the different stages of the experiment (during the allocation, the conduct of the experiment, the outcome assessment, and the data analysis).	Methods/line 131-132
Outcome measures	6	a. Clearly define all outcome measures assessed (e.g. cell death, molecular markers, or behavioural changes).	Methods/line 109-120
		b. For hypothesis-testing studies, specify the primary outcome measure, i.e. the outcome measure that was used to determine the sample size.	Methods/line 109-120
Statistical methods	7	a. Provide details of the statistical methods used for each analysis, including software used.	Methods/line 153-158
		b. Describe any methods used to assess whether the data met the assumptions of the statistical approach, and what was done if the assumptions were not met.	Methods/line 153-158
Experimental animals	8	a. Provide species-appropriate details of the animals used, including species, strain and substrain, sex, age or developmental stage, and, if relevant, weight.	Methods/line 94-102
		b. Provide further relevant information on the provenance of animals, health/immune status, genetic modification status, genotype, and any previous procedures.	Methods/line 94-102
Experimental procedures	9	For each experimental group, including controls, describe the procedures in enough detail to allow others to replicate them, including:	Methods/line 94-158
		a. What was done, how it was done and what was used.	Methods/line 94-158
		b. When and how often.	Methods/line 94-158
		c. Where (including detail of any acclimatisation periods).d. Why (provide rationale for procedures).	Methods/line 94-158
Results	10	For each experiment conducted, including independent replications, report:	Results/line160-190
Nesurs	.0	 a. Summary/descriptive statistics for each experimental group, with a measure of variability where applicable (e.g. mean and SD, or median and range). 	
		b. If applicable, the effect size with a confidence interval.	Results/line160-190

The Recommended Set

These items complement the Essential 10 and add important context to the study. Reporting the items in both sets represents best practice.

ltem		Recommendation	Section/line number, or reason for not reporting
Abstract	11	Provide an accurate summary of the research objectives, animal species, strain and sex, key methods, principal findings, and study conclusions.	Abstract/line 28-51
Background	12	 Include sufficient scientific background to understand the rationale and context for the study, and explain the experimental approach. 	Introduction/line 53-91
		 Explain how the animal species and model used address the scientific objectives and, where appropriate, the relevance to human biology. 	Introduction/line53-91
Objectives	13	Clearly describe the research question, research objectives and, where appropriate, specific hypotheses being tested.	Introduction/line53-91
Ethical statement	14	Provide the name of the ethical review committee or equivalent that has approved the use of animals in this study, and any relevant licence or protocol numbers (if applicable). If ethical approval was not sought or granted, provide a justification.	Footnote/line 265-269
Housing and husbandry	15	Provide details of housing and husbandry conditions, including any environmental enrichment.	Methods/line 94-108
Animal care and monitoring	16	 Describe any interventions or steps taken in the experimental protocols to reduce pain, suffering and distress. 	Methods/line 94-102
		b. Report any expected or unexpected adverse events.	Methods/line 94-102
		c. Describe the humane endpoints established for the study, the signs that were monitored and the frequency of monitoring. If the study did not have humane endpoints, state this.	Methods/line 94-102
Interpretation/ scientific implications	17	a. Interpret the results, taking into account the study objectives and hypotheses, current theory and other relevant studies in the literature.	Discussion/line 192-252
		b. Comment on the study limitations including potential sources of bias, limitations of the animal model, and imprecision associated with the results.	Discussion/line 192-252
Generalisability/ translation	18	Comment on whether, and how, the findings of this study are likely to generalise to other species or experimental conditions, including any relevance to human biology (where appropriate).	Discussion/line 245-252
Protocol registration	19	Provide a statement indicating whether a protocol (including the research question, key design features, and analysis plan) was prepared before the study, and if and where this protocol was registered.	Methods/194-1 02
Data access	20	Provide a statement describing if and where study data are available.	Footnote/line 2863-264
Declaration of interests	21	a. Declare any potential conflicts of interest, including financial and non-financial. If none exist, this should be stated.	Footnote/line 261-262
		 List all funding sources (including grant identifier) and the role of the funder(s) in the design, analysis and reporting of the study. 	Acknowledgments/line 254-257

Article information: https://dx.doi.org/10.21037/tp-22-475

